Neumora Therapeutics, Inc.: 1 tracked 2026 layoff event(s), 0 workers counted, highest AI score 4.
AI score 4 (80% interval 3–5) · evidence grade D · US · Pharma / Chemicals
Stated reason: On June 12, 2026, in connection with the discontinuation of development of navacaprant described below, the Company implemented a reduction in force of approximately 35%, which it expects to complete in the second and third quarters of 2026. The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately…
Why 4: Plant, store or site closure · Drivers: contrary evidence −0.6, industry AI exposure +0.5, role AI exposure +0.2
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.888, industry exposure 0.712, AI investment 0.0, contrary 0.4 · named roles: Computer Systems Analysts, Data Scientists, Software Developers
Headcount basis: not disclosed
Company AI financials (AI spending, revenue, earnings-call AI mentions) are coming soon to this page.
